Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461306 | 0.79 | S1PR1 (1.00) | S1PR1KCNH2 | |
| SCHEMBL435485 | 0.78 | S1PR1 (0.65) | S1PR1MAPK1ALDH1A1LMNAS1PR3 | |
| SCHEMBL16649289 | 0.77 | S1PR1 (0.84) | S1PR1MAPK1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL461363 | 0.76 | S1PR1 (0.65) | S1PR1MAPK1LMNAMAPTS1PR3 | |
| SCHEMBL459570 | 0.72 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL16649406 | 0.71 | S1PR1 (0.85) | S1PR1S1PR3 | |
| SCHEMBL459888 | 0.71 | S1PR1 (0.82) | S1PR1S1PR3KCNH2 | |
| SCHEMBL29077275 | 0.71 | RAB9A (0.52) | MAPK1ALDH1A1L3MBTL1LMNAMAPT | |
| SCHEMBL460497 | 0.70 | S1PR1 (0.82) | S1PR1S1PR3 | |
| SCHEMBL460137 | 0.69 | S1PR1 (0.62) | S1PR1L3MBTL1MAPTS1PR3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619190-B1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2619190-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | Bristol-Myers Squibb Company (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | claimed |
| WO-2012040532-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | claimed |
| US-9187437-B2 | Substituted oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2619190-B1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885MAPK1 691/4885ALDH1A1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.